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Abstract 
Background: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) contribute 
to Aboriginal Australian and Torres Strait Islander health disadvantage. At the time of this 
study, specialist ARF/RHD care in the Kimberley region of Western Australia was 
delivered by a broad range of providers while in far north Queensland (FNQ) a single 
provider model was used as part of a coordinated RHD control program. 
Aims: To review ARF/RHD management in the Kimberley and FNQ to ascertain whether 
differing models of service delivery are associated with different disease burden and patient 
care. 
Methods: An audit of ARF/RHD management. Classification and clinical management data 
were abstracted from health records, specialist letters, echocardiograms and regional 
registers using a standardised data collection tool. 
Results: 407 patients were identified with 99% being Aboriginal and/or Torres Strait 
Islanders. ARF without RHD was seen in 0.4% of Aboriginal and/or Torres Strait Islander 
residents and RHD in 1.1%. The prevalence of RHD was similar in both regions but with 
more severe disease in the Kimberley. More FNQ RHD patients had specialist review 
within recommended timeframes (67% versus 45%, χ2, p<0.001). Of patients 
recommended benzathine penicillin secondary prophylaxis, 17.7% received ≥80% of 
scheduled doses in the preceding 12 months. Prescription and delivery of secondary 
prophylaxis was greater in FNQ. 
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Conclusions: FNQ’s single-provider model of specialist care and centralised RHD control 
program were associated with improved patient care and may partly account for the fewer 
cases of severe disease and reduced surgical and other interventions observed in this region. 
Abstract word count: 249 
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Acute Rheumatic Fever 
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Prophylaxis 
Health Care Quality Assurance 
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(ii)Text (3162): 
Introduction 
Acute rheumatic fever (ARF) is a non-suppurative complication of infection with group A 
streptococcus (GAS). Its major chronic sequela is chronic heart valve damage associated 
with rheumatic heart disease (RHD). Rates of ARF and RHD in Aboriginal Australians and 
Torres Strait Islander peoples are among the highest documented in the world, but these 
conditions are very rare in non-Indigenous Australians.1, 2 Across the north of Australia the 
prevalence of RHD in the Aboriginal and Torres Strait Islander population has been 
reported at 1-2%.3-6 
The development of national Australian guidelines for ARF and RHD diagnosis and 
management7 have facilitated the standardisation of ARF/RHD care between Australian 
state health departments and they have been utilized to inform local management 
guidelines.8-10 Management of ARF and RHD encompasses secondary antibiotic 
prophylaxis in the form of 3-4 weekly long-acting benzathine penicillin (BP) injections to 
prevent GAS infection and recurrent ARF, regular local primary healthcare review, 
echocardiography, specialist review and education.7 Management of RHD also involves 
preventing and managing complications such as endocarditis, cardioembolism and heart 
failure, and assessing the need for valve related surgical procedures.7 
Previous studies of ARF/RHD in the north of Australia have demonstrated suboptimal care: 
secondary prophylaxis coverage is inadequate, survival following heart valve surgery is 
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low, and monitoring of anticoagulation is variable.11-13 This earlier work, and the 
demonstrated high burden of disease, has provided a focus for local initiatives which aim to 
improve access to, and quality of, care. 
The processes and models of local service delivery for comprehensive ARF/RHD care 
remain variable. This is in part due to historic models of service delivery, geography, and 
population and health workforce distribution. The Kimberley region of Western Australia 
(WA) and Cape York and Torres Strait regions of far north Queensland (FNQ) (see Figure 
1) illustrate such variability, with significantly different models of service delivery. 
At the time of this review, ARF/RHD care in the Kimberley was based on a “multi-provider 
model” centred on primary health care with support and follow-up provided by community-
based and outreach specialist service providers. These services included local regional 
physicians and paediatricians who visited large and small communities, and visiting 
cardiologists (paediatric and adult) and echocardiographers in larger centres. This involved 
public and private service providers from a number of different organisations with any 
required surgery being undertaken in one of three Perth hospitals. Individual primary health 
care sites maintained a variety of paper-based and electronic registers and recall systems 
with no single regional system. 
In FNQ, ARF/RHD care was similarly centred on primary health care but with support and 
follow-up provided by a “multi-skilled single-provider model”. This consisted of a single 
specialist outreach service of physicians (who also performed echocardiography) and 
paediatricians, with adult or paediatric cardiology review generally only provided when 
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surgery was planned at regional referral centres (Cairns or Townsville). Registration and 
recall of ARF/RHD patients was provided from a regional database supported and 
coordinated by a centralised ARF/RHD program.   
In order to explore optimal models of care for people with ARF/RHD living in the north of 
Australia we undertook an assessment of these two differing systems. This included an 
assessment of the locally recognised burden of disease, an audit of the care received by 
patients, and benchmarking care against local management guidelines. This process focused 
on the performance and coordination of care across each region rather than on individual 
providers.  
Materials and Methods 
We reviewed the management of ARF/RHD patients who had accessed primary and 
specialist health care services in the Kimberley region of northern WA and in the Cape 
York and Torres Strait regions of FNQ (see Figure 1). In the Kimberley, these services 
were provided by Aboriginal community-controlled health services and/or state health 
department primary health care clinics and hospitals. In FNQ they were predominantly 
provided by health department primary health care clinics and hospitals. 
Inclusion criteria were a clinician-recorded diagnosis of either (1) ARF and/or (2) RHD in 
patients considered by the local health service to be “regular” clients. A diagnosis of ARF 
required health record documentation of ARF (irrespective of time of diagnosis and 
whether ARF currently actively managed) or the use of an ARF care plan and, where 
available, no evidence of RHD on the most recent echocardiogram report. A diagnosis of 
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RHD required documentation of RHD by the local health service with an associated 
abnormal echocardiogram, or a history of prosthetic valve replacement/valve 
repair/valvuloplasty, or an echocardiogram report consistent with RHD. Consistent 
echocardiography findings included: mitral stenosis, mitral regurgitation with thickening 
and/or distortion of the valve leaflets, or mitral valve and aortic valve regurgitation or 
stenosis.  
Eligible patients were identified at local health services through interrogation of health 
information management systems (i.e. searching for clients assigned to an ARF/RHD “care 
plan”, or generating ARF/RHD “problem” lists), accessing BP recall lists, and through 
questioning of  local health service staff. In FNQ the regional ARF/RHD register was also 
accessed to identify potential clients for inclusion. Finally, electronic copies of specialist 
letters and echocardiography reports were searched for terms that may indicate the client 
had ARF/RHD (e.g. rheumatic, mitral, aortic, valve, regurgitation, stenosis) and the health 
records of clients identified through these methods checked for diagnoses . 
Data were collected in the Kimberley between August and November 2007 at 17 primary 
health care sites and in FNQ between November 2008 and March 2009 at 12 sites (Figure 
1). Data on clinical management were abstracted from local health records (paper-based 
and electronic), specialist letters, echocardiogram reports, and local and regional registers 
and recall databases. A standardised data collection tool was utilised with a manual 
providing standardised definitions for patient selection and service delivery.  
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Data collected and quality measures assessed included: patient demographics; 
echocardiogram timeliness and results; severity of ARF/RHD based on the classification 
system proposed by the national guidelines7 (see Table 1); prescription and uptake of 
secondary prophylaxis in the 12 months prior to audit; timeliness of specialist review 
(cardiologist, physician, paediatrician); uptake of immunisations (influenza vaccination 
within past 12 months, pneumococcal vaccination within last 5 years); and appropriateness 
of anticoagulation. The delivery of health services was benchmarked against local standards 
of care as outlined in the Kimberley chronic disease protocols9 and Queensland chronic 
disease guidelines10 (see Table 2). For those clients receiving secondary prophylaxis, the 
proportion achieving >=80% of scheduled doses in the 12 months prior to audit was 
calculated and any episodes of recurrent ARF for that period recorded. 
Population denominators were based on 2006 Australian Bureau of Statistics census data.14 
Disease prevalence in the Kimberley was based on the entire Aboriginal and Torres Strait 
Islander population of the region as clients from all possible health care sites were included. 
Disease prevalence in FNQ was based on population statistics for Local Government Areas 
(LGAs) associated with those sites audited. Data from Thursday Island were excluded as 
accurate population denominator data were not available.  
Data were analysed using SPSS (v15.0 for Windows, SPSS Inc, Chicago, IL, USA) and 
Intercooled Stata 12 (Stata Corporation, Texas, USA). All statistical tests were two-sided 
with a p-value < 0.05 taken to indicate statistical significance. 
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This project was approved as a clinical audit by the Western Australian Aboriginal Health 
Information and Ethics Committee (WAAHIEC), the Western Australia Country Health 
Service Board Research Ethics Committee, and the Human Research Ethics Committee of 
the Cairns and Hinterland Health Service District, Queensland Health. 
Results: 
407 patients were included in the study. Patient demographics, disease prevalence and 
severity, and valve surgery/procedures are presented in Table 3. There were no significant 
differences in the demographics of Kimberley and FNQ patients. The prevalence of a 
previous diagnosis of ARF (with no progression to RHD) and RHD was similar in the two 
study areas but with more severe disease in the Kimberley. Significantly more RHD 
patients in the Kimberley had undergone valve surgery or associated procedures. 
A history of ARF without associated RHD was seen in 24.5% (52/212) of Kimberley 
patients and 27.7% (54/195) of FNQ patients. Median age was 22.4 years (IQR 17.2 – 32.4) 
and women were overrepresented, accounting for 60.2% of patients. There was no 
significant difference in age or gender between Kimberley and FNQ ARF patients. 
In people with a history of ARF it is recommended that an echocardiogram be performed at 
the time of diagnosis (to assess for carditis and pre-existent RHD) and prior to ceasing 
prophylaxis. FNQ ARF patients were more likely to have had any echocardiogram 
performed with 96% (52/54) having a record of an echocardiogram compared with 85% 
(44/52) of Kimberley patients (χ2, p < 0.05). 
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Evidence of RHD was seen in 75.5% (160/212) of Kimberley and 72.3% (141/195) of FNQ 
participants. Median age was 30 years (IQR 20 to 43) and women were again 
overrepresented, accounting for 71.8% of patients. 
Overall 55.1% (166/301) of RHD patients had had a specialist review by a paediatrician, 
physician or cardiologist in concordance with timeframes recommended in local 
management guidelines. Timely specialist review was more likely for FNQ RHD patients 
(66.7%, 94/141) compared with Kimberley patients (45.0%, 72/160) (χ2, p<0.001).  
Echocardiography was delivered to 60.5% (182/301) of RHD patients within recommended 
timeframes with no overall difference between regions. However, RHD patients in the 
Kimberley who had a history of valve surgery or other procedures were more likely to have 
received a timely echocardiogram than comparable patients in FNQ (31/44 (70.5%) versus 
9/23 (39.1%), χ2, p<0.001). 
The delivery of secondary antibiotic prophylaxis to ARF/RHD patients is outlined in Table 
4. The proportion of patients receiving BP prophylaxis was significantly higher in FNQ 
than in the Kimberley (χ2, p<0.001) as was the median number of doses given in the twelve 
months prior to audit (Wilcoxan Mann-Whitney test, p<0.0001). Ten patients in FNQ and 
two in the Kimberley with a recommendation for benzathine penicillin prophylaxis had an 
episode of recurrent ARF in the 12 months prior to the study (Fisher’s exact test, p<0.05). 
All of these cases were preventable with no patient receiving adequate secondary antibiotic 
prophylaxis in the 2 months prior to their episode of recurrent ARF. 
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One in five RHD patients was receiving warfarin anticoagulation (see Table 5). Based on a 
recommended frequency of INR monitoring of six weekly15, 36.7% of these had inadequate 
monitoring. Of all recorded INR results 65.1% were outside the recommended range.7 No 
significant differences were observed between FNQ and the Kimberley. 
Influenza and pneumococcal vaccinations were recommended for all patients with 
ARF/RHD. Influenza and pneumococcal vaccination was more likely to be up-to-date in 
FNQ patients (influenza 54.4%, pneumococcal 47.7%) compared with Kimberley patients 
(38.6%, 37.3%) (χ2, p<0.01 and p<0.05 respectively). 
Discussion 
This study is the first to highlight differences in the nature and burden of ARF/RHD, and 
the quality of care received by ARF/RHD patients in different northern Australian regions.  
Results from this study confirm that in northern Australia ARF/RHD remains almost 
exclusively a disease of Aboriginal and Torres Strait Islander people with 99% of identified 
ARF/RHD patients being of Aboriginal and/or Torres Strait Islander ethnicity). The  
observed prevalence of RHD in Aboriginal and Torres Strait Islander people in the 
Kimberley (1.02%) and FNQ (1.14%) was comparable to earlier studies of Aboriginal 
Australian and low income country populations.2, 3, 6, 16 This is in contrast to the waning 
burden of disease among other Australians (0.2% in the Top End of the Northern Territory 
and less than 0.1% in Central Australia)6 and most other high income nations.16, 17 
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The relatively young median age of RHD patients in this study is presumably related to 
premature mortality of people with RHD in this setting. This is supported by evidence from 
the Northern Territory where the mean age at death of Aboriginal people with RHD is 35.7 
years compared to 67.3 years in non-Aboriginal RHD patients.1 
The predominance of female patients has been noted previously.2, 6 Whilst the cause of this 
remains unclear it has been suggested that a greater exposure to GAS associated with the 
care of children, enhanced diagnosis accompanying more frequent health care utilisation 
and a gender-related propensity to autoimmune disease may all contribute.18 
While the overall prevalence of ARF/RHD was similar in both regions we demonstrated a 
greater proportion of severe RHD and higher levels of valve related procedures in the 
Kimberley. This difference may be explained by regional differences in the pattern of 
ARF/RHD, differences in diagnosis and monitoring, and uptake of secondary antibiotic 
prophylaxis. 
ARF/RHD is associated with economic and environmental disadvantage19, 20 and incidence 
of infection with GAS21. The available data do not suggest differences in housing, 
employment, degree of remoteness or income between the Kimberley and FNQ22 and there 
is no obvious reason to suspect that the natural history of ARF/RHD differs between the 
two regions. 
It is possible that cases of ARF and/or mild RHD were not as readily identified in the 
Kimberley as in FNQ. In FNQ we observed a significantly greater proportion of ARF/mild 
RHD which may indicate that cases were being identified earlier here. Earlier identification 
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would enable earlier intervention, including delivery of secondary prophylaxis to prevent 
the development or worsening of RHD, thereby ensuring that fewer patients progress to 
severe disease or require heart surgery. In Queensland there was a centralised RHD control 
program and a regional ARF/RHD database in place at the time of this study. This program 
incorporated an ARF notification system, a centralised coordination unit, regular reminders 
to health providers about individuals requiring BP prophylaxis and specialist follow-up, 
and ongoing training and support for health staff in relation to the management of 
ARF/RHD. In contrast, at the time there was no such program or regional ARF/RHD 
database in the Kimberley. This difference in the coordination of care may be associated 
with the differences in observed service delivery and disease severity between the two 
regions. An ARF/RHD enhanced surveillance system similar to the one in place in FNQ 
has since been implemented in the Kimberley.  
While we did demonstrate lower levels of echocardiography in ARF patients without RHD 
in the Kimberley, the use of echocardiography (and thus diagnosis and monitoring of 
severity) in those with RHD was comparable between regions. Differences in monitoring of 
disease severity alone do not explain the differences in disease severity observed. 
More severe disease was associated with less delivery of secondary antibiotic prophylaxis 
and less specialist review in the Kimberley compared to FNQ. Even if the greater use of 
less effective oral antibiotic secondary prophylaxis23 in FNQ was excluded, 16% more 
patients were prescribed BP prophylaxis and the median number of BP doses delivered was 
75% greater in FNQ. Greater delivery of secondary antibiotic prophylaxis in FNQ would be 
expected to have led to fewer episodes of recurrent ARF and hence less disease 
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progression. The recorded rate of recurrent ARF was, however, significantly higher in 
FNQ. At the time, ARF was a notifiable disease in FNQ but not in the Kimberley 
suggesting that episodes of recurrent ARF were more likely to be reported in FNQ and that 
significant under-reporting and perhaps under-recognition was occurring in the Kimberley. 
The delivery of specialist services observed in both the Kimberley and FNQ was less than 
optimal with only 55.1% of RHD patients being reviewed within recommended timeframes 
and 60.5% receiving a timely echocardiogram. An earlier study in the Kimberley reported 
that of those patients recommended visiting specialist or echocardiographic review, 78% 
and 64% attended respectively.11 Similarly, in the Northern Territory, while RHD patients 
with severe disease were usually receiving follow-up, approximately half the people with 
moderate and mild disease had been inadequately investigated and/or had not received 
follow-up.12 
RHD patients in FNQ were more likely to have been seen by a specialist within 
recommended timeframes. This was confined to patients with RHD who had not undergone 
heart valve surgery (data not shown). More frequent specialist review in FNQ may have 
enhanced the uptake of secondary antibiotic prophylaxis and thus impeded the progression 
of disease, but it is not possible to confirm this. Despite more frequent specialist review in 
FNQ, by a workforce who provided contemporaneous echocardiography, and a centralised 
recall system, there was no difference in the delivery of echocardiography services to RHD 
patients in the Kimberley and FNQ. Indeed Kimberley RHD patients with a history of valve 
surgery or other procedures were more likely to have received a timely echocardiogram 
compared with FNQ patients. Specialist-provided echocardiography in FNQ, while 
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apparently more frequently available, may have been deferred in busy clinics with other 
clinical priorities. A dedicated echocardiography service such as that used in the Kimberley 
is not subject to similar distraction and appears to have ensured those with more advanced 
disease had echocardiography performed as scheduled. 
 Many patients with advanced RHD, in particular those who have a mechanical valve in 
situ, require anticoagulation. Delivery of anticoagulation therapy to RHD patients was 
suboptimal. The lack of concordance between INR targets recommended by national 
guidelines7 and those recorded in patient notes is concerning, as is the finding that 1/3 of 
patients on warfarin did not receive adequate monitoring and that almost 2/3 of recorded 
INR results were outside recommended targets. A study in non-remote Australia found 
therapeutic anticoagulation in 57.6% of tests compared with 34.9% seen here.24 It is vital 
that initiatives be developed to address this issue in these remote Australian settings. Newer 
oral anticoagulants which do not require INR monitoring have been developed, however 
evidence of their effectiveness in RHD, atrial fibrillation related to valvular disease, and 
mechanical valves is lacking.25 Given the difficulties associated with anticoagulation and 
INR monitoring demonstrated here, balloon valvuloplasty, valve repair or bioprosthetic 
valve replacement are clearly preferable (where they are an option) for patients living in 
remote northern Australia. 
While the differences in delivery of health services observed in this study, particularly the 
higher levels of BP prescription and delivery and the more timely specialist review 
observed in FNQ, may be associated with the differing models of service delivery in the 
two regions, it is important to note that data was collected in the Kimberley in 2007 while 
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data was collected in FNQ in 2008-2009. The national Australian guidelines for ARF and 
RHD diagnosis and management7 were published in 2006 and it is possible that one reason 
for improved concordance in FNQ was that the extra time between publication and audit in 
FNQ may have enabled the implementation of awareness programs, education initiatives 
and system changes to align more closely with the guidelines. 
Conclusion 
This study has documented the nature, burden and management of ARF/RHD in two 
regions of northern Australia. We have demonstrated differences in disease severity that 
may, at least in part, be explained by differing levels of secondary prophylaxis uptake, 
differing specialist access and the presence or absence of a centralised ARF/RHD control 
program. In both regions specialist and echocardiography services, secondary prophylaxis 
and the management of anticoagulation have changed little over the last decade.11, 12 
Coordinated systems for ARF/RHD management supported by centralised database and 
recall systems and a consolidated specialist health care team were associated with improved 
patient care and may partly account for fewer cases of severe  disease  and a reduced 
number of surgical and other interventions observed in FNQ. 
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(v) Figure Legends 
Figure 1: Study sites in the Kimberley (Western Australia) and far north Queensland.
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(vi) Tables 
Table 1: Protocol-based classification of severity of acute rheumatic fever and rheumatic 
heart disease7 
Classification Criteria 
Mild 
ARF with no evidence of RHD; or trivial to mild valvular 
disease. 
Moderate 
Any moderate valve lesion in the absence of symptoms and with 
normal left ventricular function; or mechanical prosthetic valves. 
Severe 
Severe valvular disease; or moderate to severe valvular lesions 
with symptoms – shortness of breath, tiredness, oedema, angina 
or syncope; or tissue prosthetic valves and valve repairs. 
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Table 2: Recommended timeframe for delivery of health services to clients with ARF/RHD 
based on local standards of care as outlined in the Kimberley chronic disease protocols9 
(KIMB) and Queensland chronic disease guidelines10 (QLD). 
  
Priority Low Moderate High 
 KIMB QLD KIMB QLD KIMB QLD 
Specialist review 2 years 2 years 1 year 6 months 6 months 3 months 
Echocardiography 
review 
2 years 1 year 1 year 1 year 1 year 6 months 
Dental review 2 years 1 year 1 year 1 year 1 year 1 year 
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Table 3: Demographics, ARF/RHD severity (see table 1) and prevalence and type of valve 
surgery/procedure in patients included in this study. († Inter-quartile range, *χ2, p<0.0001, 
**χ2, p<0.05) 
 
 
All patients 
(n = 407) 
Kimberley 
(n = 212) 
FNQ 
(n = 195) 
Age, median years (IQR†) 
29.1 
(18.7 – 40.2) 
29.4 
(19.2 - 41.0) 
27.4 
(18.3 – 39.5) 
Female, n (%) 280 (68.8%) 141 (66.5%) 139 (71.3%) 
Aboriginal and/or Torres 
Strait Islander, n (%) 
403 (99.0%) 211 (99.5%) 192 (98.5%) 
Disease prevalence in 
Aboriginal and/or Torres 
Strait Islander population, % 
   
ARF (no progression to RHD) 0.36% 0.33% 0.41% 
RHD 1.07% 1.02% 1.14% 
Disease severity, n (%)    
ARF / Mild RHD 237 (58.2%) 101 (47.6%) 136 (69.7%)* 
Moderate RHD 66 (16.2%) 38 (17.9%) 28 (14.4%) 
Severe RHD 104 (25.6%) 73 (34.4%) 31 (15.9%)* 
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Valve surgery or procedures, 
n (% RHD patients) 
   
Any valve surgery/procedure 67 (22.3%) 44 (27.5%) 23 (16.3%)** 
Mechanical valve 36 (12%) 24 (15%) 12 (8.5%) 
Bioprosthetic valve 13 (4.3%) 9 (5.6%) 4 (2.8%) 
Valvuloplasty/repair 18 (6%) 11 (6.9%) 7 (5.0%) 
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Table 4. Recommendation for, and delivery of, secondary antibiotic prophylaxis in the 12 
months prior to review. (*χ2, p<0.001; **Wilcoxan Mann-Whittney test, p < 0.0001; *** 
Fisher’s exact test, p<0.0001; †benzathine penicillin) 
 
All patients 
(n = 407) 
Kimberley 
(n = 212) 
FNQ 
(n = 195) 
Recommendation or prescription for BP† 
n (%) 
293 
(72.0%) 
136 
(64.2%) 
157* 
(80.5%) 
> 80% doses BP given 
n (% of those recommended BP) 
52/293 
(17.7%) 
20/136 
(14.7%) 
32/157 
(20.4%) 
Number of doses of BP 
median (IQR†) 
6 
(2-8) 
4 
(1.5-8) 
7** 
(4-9) 
Recommendation for oral antibiotics 
n (%) 
21/407 
(5.2%) 
0 
(0%) 
21/195*** 
(10.8%) 
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Table 5: Anti-coagulation therapy and RHD in the Kimberley and FNQ (†national guideline 
INR recommendations7: atrial fibrillation without mechanical valve replacement 2 to 3; 
mechanical mitral valve 2.5 to 3.5; mechanical aortic valve2 to 3. ‡ Based on a minimum 
recommended monitoring interval of 6 weeks15) 
 
All 
(n=301) 
Kimberley 
(n=160) 
FNQ 
(n=141) 
RHD patients on warfarin, n (%) 60/301 (19.9%) 37/160 (23.1%) 23/141(16.3%) 
Primary indication for warfarin, n (%)    
Mechanical valve 35/60 (58.3%) 24/37 (64.9%) 11/23 (47.8%) 
Atrial fibrillation 19/60 (31.7%) 10/37 (27.0%) 9/23 (39.1%) 
Mitral valve disease 6/60 (10.0%) 3/37 (8.1%) 3/23 (13.1%) 
Target INR, n (%)    
Documented in medical record? 49/60 (81.7%) 29/37 (78.4%) 20/23 (87.0%) 
Concordant with national guidelines?† 19/49 (38.8%) 8/29 (27.6%) 11/20 (55.0%) 
INR tests in previous 12 months    
Number, median (IQR) 11 (5 – 21.5) 15 (5 – 26) 9 (6.5 – 12) 
Adequate testing‡, n (%) 38/60 (63.3%) 23/37 (62.2%) 15/23 (65.2%) 
Results above recommended range, n (%) 180/758 (23.7%) 129/517 (25.0%) 51/241 (21.2%) 
Results below recommended range, n (%) 314/758 (41.4%) 232/517 (44.9%) 82/241 (34.0%) 
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(vii) Figures 
Figure 1: 
 
